Anti-tumor activities of dexamethasone

Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects

Volumn , Issue , 2013, Pages 117-136

  Ishiguro, Hitoshi ^a,b   Kawahara, Takashi ^a,b   Li, Yi ^a,c   Miyamoto, Hiroshi ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892243615     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (82)

1. Basch E, Prestrud A. A, Hesketh P. J, Kris M. G, Feyer P. C, Somerfield M. R, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 29: 4189-4198, 2011.
2. Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell. Endocrinol. 275: 2-12, 2007. (" Cell." for " Cellular" )
3. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: Molecular mechanisms for gene repression. Endocr. Rev. 24: 488-522, 2003.
4. Sumikawa T, Shigeoka Y, Igishi T, Suyama H, Yamasaki A, Hashimoto K, et al. Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. Int. J. Oncol. 32: 683-688, 2008.
5. Qian Y-H, Xiao Q, Chen H, Xu J. Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway. Biochim. Biophys. Acta. 1793: 764-771, 2009.
6. Chen Y-X, Wang Y, Fu C-C, Diao F, Song L-N, Li Z-B, et al. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr. Relat. Cancer. 17: 39-50, 2010.
7. Ge H, Ni S, Wang X, Xu N, Liu Y, Wang L, et al. Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer. PLoS One. 7: e51821, 2012.
8. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 11 (Suppl 1): S45-S55, 2004.
9. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63: 11-30, 2013.
10. Alexanian R, Haut A, Khan A. U, Lane M, McKelvey E. M, Migliore P. J, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208: 1680-1685, 1969.
11. Facon T, Mary J. Y, Pégourie B, Attal M, Renaud M, Sadoun A, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 107: 1292-1298, 2006.
12. Alexanian R, Dimopoulos M. A, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 80: 887-890, 1992.
13. Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamaqni E, et al. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Hematologica. 87: 934-942, 2002.
14. Attal M, Harousseau JL, Stoppa A. M, Sotto J. J, Fuzibet J. G, Rossi J. F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 335: 91-97, 1996.
15. Chen H-F, Li Z-Y, Tang J-Q, Shen H-S, Cui Q-Y, Ren Y-Y, et al. Clinical study of thalidomide combined with dexamethasone for the treatment of elderly patients with newly diagnosed multiple myeloma. Asian Pac. J. Cancer Prev. 13: 4777-4781, 2012.
16. Mattano L. A Jr., Devidas M, Nachman J. B, Sather H. N, Hunger S. P, Steinherz P. G. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: Results from the CCG1961 randomised cohort trial. Lancet Oncol. 13: 906-915, 2012.
17. Kaspers G. J, Pieters R, Klumper E, De Waal F. C, Veerman A. J. Glucocorticoid resistance in childhood leukemia. Leuk. Lymphoma. 13: 187-201, 1994.
18. Renner K, Ausserlechner M. J, Kofler R. A conceptual view on glucocorticoid-lnduced apoptosis, cell cycle arrest and glucocorticoid resistance in lymphoblastic leukemia. Curr. Mol. Med. 3: 707-717, 2003.
19. Tissing W. J, Meijerink J. P, den Boer M. L, Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia. 17: 17-25, 2003.
20. Bostrom B. C, Sensel M. R, Sather H. N, Gaynon P. S, La M. K, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from Children's Cancer Group. Blood. 101: 3809-3817, 2003.
21. Singer E. A, Golijanin D. J, Miyamoto H, Messing E. M. Androgen deprivation therapy for prostate cancer. Expert Opin. Pharmacother. 9: 211-228, 2008.
22. Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene. 26: 1885-1896, 2007.
23. Szmulewitz R. Z, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, et al. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 72: 157-164, 2012.
24. Millikan R. E. Chemotherapy of advanced prostatic carcinoma. Semin. Oncol. 26: 185-191, 1999.
25. Miller G. M, Hinman F Jr. Cortisone treatment in advanced carcinoma of the prostate. J. Urol. 72: 485-496, 1954.
26. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 7: 590-597, 1989.
27. Patel S. R, Kvols L. K, Hahn R. G, Windschitl H, Levitt R, Therneau T. A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer. 66: 655-658, 1990.
28. Storlie J. A, Buckner J. C, Wiseman G. A, Burch P. A, Hartmann L. C, Richardson R. L. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 76: 96-100, 1995.
29. Kelly W. K, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher H. I. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J. Clin. Oncol. 13: 2208-2213, 1995.
30. Tannock I. F, Osoba D, Stockler M. R, Ernst D. S, Neville A. J, Moore M. J, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14: 1756-1764, 1996.
31. Nishiyama T, Terunuma M. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int. J. Urol. 5: 44-47, 1998.
32. Sartor O, Weinberger M, Moore A, Li A, Figg W. D. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology. 52: 252-256, 1998.
33. Kantoff P. W, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormonerefractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17: 2506-2513, 1999.
34. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 89: 2570-2576, 2000.
35. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J. Urol. 168: 2439-2443, 2002.
36. Small E. J, Meyer M, Marshall M. E, Reyno L. M, Meyers F. J, Natale R. B, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J. Clin. Oncol. 18: 1440-1450, 2000.
37. Saika T, Kusaka N, Tsushima T, Yamato T, Ohashi T, Suyama B, et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int. J. Urol. 8: 290-294, 2001.
38. Fossa S. D, Slee P. H, Brausi M, Horenblas S, Hall R. R, Hetherington J. W, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J. Clin. Oncol. 19: 62-71, 2001.
39. Morioka M, Kobayashi T, Furukawa Y, Jo Y, Shinkai M, Matsuki T, et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol. Int. 68: 10-15, 2002.
40. Fuse H, Nozaki T, Fujiuchi Y, Mizuno I, Nagakawa O, Okumura A. Treatment with prednisolone of hormone-refractory prostate cancer. Arch. Androl. 52: 35-38, 2006.
41. Komiya A, Shimbo M, Suzuki H, Imamoto T, Kato T, Fukasawa S, et al. Oral low-dose dexamethasone for androgen-independent prostate cancer patients. Oncol. Lett. 1: 73-79, 2010.
42. Diaz J. F, Andreu J. M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 32: 2747-2755, 1993.
43. Haldar S, Basu A, Croce C. M. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57: 229-233, 1997.
44. Kawahara T, Miyoshi Y, Sekiguchi Z, Sano F, Hayashi N, Teranishi J, et al. Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel. PLoS One. 7: e48186, 2012.
45. Tannock I. F, de Wit R, Berry W. R, Horti J, Pluzanska A, Chi K. N, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351: 1502-1512, 2004.
46. Pond G. R, Armstrong A. J, Wood B. A, Brookes M, Leopold L, Berry W. R, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur. Urol. 61: 363-369, 2012.
47. Hatano K, Nishimura K, Nakai Y, Yoshida T, Sato M, Kawashima A, et al. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic casstration-resistant prostate cancer. Int. J. Clin. Oncol., 2012 (in press).
48. Miyoshi Y, Uemura H, Nakamura M, Hasumi H, Sugiura S, Makiyama K, et al. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int. J. Clin. Oncol. 10: 182-186, 2005.
49. Weitzman A. L, Shelton G, Zuech N, Owen C. E, Judge T, Benson M, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J. Urol. 163: 834-837, 2000.
50. Dietrich K, Schned A, Fertuny J, Heaney J, Marsit C, Kelsey K. T, et al. Glucocorticoid therapy and risk of bladder cancer. Br. J. Cancer. 101: 1316-1320, 2009.
51. Zhang C, Mattern J, Haferkamp A, Pfitzenmaier J, Hohenfellner M, Rittgen W, et al. Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol. Ther. 5: 59-64, 2006.
52. Zheng Y, Izumi K, Li Y, Ishiguro H, Miyamoto H. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasonemediated glucocorticoid receptor signals. Mol. Cancer Ther. 11: 26212632, 2012.
53. Kaup B, Schindler I, Knüpfer H, Schlenzka A, Preiss R, Knüpfer M. M. Time-dependent inhibition of glioblastoma cell proliferation by dexamethasone. J. Neurooncol. 51: 105-110, 2001.
54. Villeneuve J, Galarneau H, Beaudet M. J, Tremblay P, Chernomoretz A, Vallières L. Reduced glioma growth following dexamethasone or antiangiopoietin 2 treatment. Brain Pathol. 18: 401-414, 2008.
55. Wang H, Li M, Rinehart J. J, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin. Cancer Res. 10: 1633-1644, 2004.
56. Lin Y-M, Jan H-J, Lee C-C, Tao H-Y, Shih Y-L, Wei H-W, et al. Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism. Eur. J. Pharmacol. 593: 1-9, 2008.
57. Zhou F, Bouillard B, Pharaboz-Joly M. O, Andre J. Nonclassical antiestrogenic actions of dexamethasone in variant MCF-7 human breast cancer cells in culture. Mol. Cell. Endocrinol. 66: 189-197, 1989.
58. Gong H, Jarzynka M. J, Cole T. J, Lee J. H, Wada T, Zhang B, et al. Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res. 68: 73867393, 2008.
59. Honorat M, Mesnier A, Di Pietro A, Lin V, Cohen P, Dumontet C, et al. Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem. Biophys. Res. Commun. 375: 308-314, 2008.
60. Lu Y-S, Lien H-C, Yeh P-Y, Kuo S-H, Chang W-C, Kuo M-L, et al. Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer. 53: 303-310, 2006.
61. Greenberg A. K, Hu J, Basu S, Hay J, Reibman J, Yie TA, et al. Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators. Am.J. Respir. Cell Mol. Biol. 27: 320-328, 2002.
62. Sommer P, Le Rouzic P, Gillingham H, Berry A, Kayahara M, Huynh T, et al. Glucocorticoid receptor overexpression exerts an antisurvival effect on human small cell lung cancer cells. Oncogene. 26: 7111-7121, 2007.
63. Feldman B. J, Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer. 1: 34-45, 2001.
64. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J. Natl. Cancer Inst. 93: 1739-1746, 2001.
65. Akakura K, Suzuki H, Ueda T, Komiya A, Ichikawa T, Igarashi T, et al. Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate. 56: 106-109, 2003.
66. Gao Q-Z, Lu J-J, Liu Z-D, Zhang H, Wang S-M, Xu H. Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-related kinase 1/2 pathway and cyclin D1 expression. Asian J. Androl. 10: 635-641, 2008.
67. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin. Cancer Res. 12: 3003-3009, 2006.
68. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin. Cancer Res. 12: 6012-6017, 2006.
69. Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br. J. Cancer. 199: 2054-2064, 2008.
70. Yam H. F, Wang Z. H, Or P. C, Wang S. W, Li J, Chew E. C. Effect of glucocorticoid hormone on nuclear matrix in cervical cancer cell. in vitro. Anticancer Res. 18: 209-216, 1998.
71. Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol. Endocrinol. 13: 1811-1822, 1999.
72. Lu Y-S, Yeh P-Y, Chuang S-E, Gao M, Kuo M-L, Cheng A-L. Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-κB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. J. Endocrinol. 188: 311-319, 2006.
73. Hayashido Y, Shirasuna K, Sugiura T, Nakashima M, Matsuya T. Effect of dexamethasone on invasion of human squamous cell carcinoma cells into collagen gel. Cancer Lett. 108: 81-86, 1996.
74. Shiratsuchi T, Ishibashi H, Shirasuna K. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. J. Cell. Physiol. 193: 340-348 2002.
75. Shim S-H, Hah J. H, Hwang S-Y, Heo D. S, Sung M-W. Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line. Oncol. Rep. 23: 1139-1143.
76. Murakami N, Fukuchi S, Takeuchi K, Hori T, Shibamoto S, Ito F. Antagonistic regulation of cell migration by epidermal growth factor and glucocorticoid in human gastric carcinoma cells. J. Cell. Physiol. 176: 127-137, 1998.
77. Iwai A, Fujii Y, Kawakami S, Takazawa R, Kageyama Y, Yoshida M. A, et al. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol. Cell. Endocrinol. 226: 1117, 2004.
78. Arai Y, Nonomura N, Nakai Y, Nishimura K, Oka D, Shiba M, et al. The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro. Cancer Invest. 26: 35-40, 2008.
79. Egberts J. H, Schniewind B, Pätzold M, Kettler B, Tepel J, Kalthoff H, et al. Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol. Ther. 7: 1044-1050, 2008.
80. Evans-Storms R. B, Cidlowski J. A. Delineation of an antiapoptotic action of glucocorticoids in hepatoma cells: The role of nuclear factor-κB. Endocrinology. 141: 1854-1862, 2000.
81. Dobos J, Kenessey I, Tímár J, Ladányi A. Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. Pathol. Oncol. Res. 17: 729-734, 2011.
82. Rogatsky, I, Trowbridge J. M, Garabedian M. J. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Mol. Cell. Biol. 17: 3181-3193, 1997.